Coherus Oncology, Inc. (CHRS) Gross margin 2019–2025
Coherus Oncology, Inc. (CHRS) gross margin by fiscal year — reported gross profit divided by reported revenue.
67.2%FY2025 · since FY2019: 95.2% → 67.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 67.2% | +0.3 pp |
| FY2024 | 66.9% | +28.7 pp |
| FY2023 | 38.2% | -28.6 pp |
| FY2022 | 66.8% | -15.6 pp |
| FY2021 | 82.4% | -9.7 pp |
| FY2020 | 92.1% | -3.1 pp |
| FY2019 | 95.2% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CHRS financial trends
CHRS RevenueCHRS Net incomeCHRS Net marginCHRS Gross profitCHRS Operating incomeCHRS Operating marginCHRS Operating cash flowCHRS Free cash flowCHRS Capital expendituresCHRS Return on equityCHRS Stock buybacksCHRS Dividends paidCHRS Total assetsCHRS Total liabilitiesCHRS Shareholders’ equityCHRS overview →